TCTR20210923013尚未招募3 期
Immunogenicity and safety after vaccinated with BBIBP-CorV (COVID-19 vaccine) in Thai pregnant women
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- Female
入选标准
- •Thai pregnant women, vaccinated with BBIBP-CorV at Chulabhorn Hospital
- •- Age at least 18 years old
- •- Gestational age at 1st vaccinated at least 12 complete weeks, confirmed by ultrasonographic measurement
- •- Willing to keep contact for information after vaccinated
- •- No history of fever or illness within 14 days before vaccinated
- •- Not been diagnosed of SARS-CoV-2 infected
- •- Not been vaccinated with any other type SARS-CoV-2 vaccine
排除标准
- •- Deny to complete 2-doses of BBIBP-CorV vaccine
- •- Multiple gestation
- •- Immunocompromised or receiving immunosupressive agents
- •- Anaphylaxis allergic reaction to BBIBP-CorV vaccine
- •- Diagnosed with any congenital infections such as Rubella, Toxoplasmosis, Parvovirus B-19, Zika virus or Syphilis
- •- Fetal structural or chromosome abnormalities, or abnormal prenatal aneuploidy screening has not yet been confirmed
研究者
相似试验
进行中（未招募）
不适用
Immune respons after TB-vaccinatioEUCTR2011-005653-31-NLMC, Department Infection Disease25
已完成
不适用
Immunological effects of BCG on vaccination with the yellow fever vaccine.Immune modulationmodulation of the immune system10002252NL-OMON40902niversitair Medisch Centrum Sint Radboud30
进行中（未招募）
不适用
Safety and Immunogenicity of Booster Vaccination with PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Booster Vaccination with Infanrix® hexa when Both Vaccines Are Co-Administered with Prevenar® to Toddlers 11-18 Months of AgePEDIACEL is a fully liquid combination vaccine indicated for infants and children for the prevention of five infectious diseases (diphtheria, tetanus, pertussis, poliomyelitis and infections caused by Haemophilus influenzae type b), as a booster dose administered to toddlers previously primed with three doses of a hexavalent vaccine.EUCTR2006-000898-30-DESanofi Pasteur Incorporated
进行中（未招募）
不适用
Evaluation of the immune response and safety of a booster dose of Pfizer's13-valent pneumococcal conjugate vaccine in children primed with 2 dosesof either GSK's 10-valent pneumococcal conjugate vaccine or Pfizer's 13-valent pneumococcal conjugate vaccine in the Slovak RepublicTo induce appropriate protection against pneumococcal disease. Toassess non-inferiority of OPA response for serotype 19A after boosterdose of PCV13 administered between 11-12 months of age in subjectsprimed with 10Pn-PD-DiT vs those primed with PCV13.EUCTR2012-005367-27-SKBIOVOMED
进行中（未招募）
不适用
Evaluation of the immune response and safety of a booster dose of Pfizer’s 13-valent pneumococcal conjugate vaccine in children primed with 3 doses of either GSK’s 10-valent pneumococcal conjugate vaccine or Pfizer’s 13-valent pneumococcal conjugate vaccine in the Czech Republic.To induce appropriate protection against pneumococcal disease. To assess non-inferiority of OPA response for serotype 19A after booster dose of PCV13 administered between 12-15 months of age in subjects primed with 10Pn-PD-DiT vs those primed with PCV13.EUCTR2012-005366-35-CZBIOVOMED